Clinical Research Papers:

Clinical outcome and prognostic factors of patients with early-stage epithelial ovarian cancer

Wei Wei _, Ning Li, Yangchun Sun, Bin Li, Lily Xu and Lingying Wu

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:23862-23870. https://doi.org/10.18632/oncotarget.13317

Metrics: PDF 1479 views  |   HTML 2730 views  |   ?  


Wei Wei1, Ning Li1, Yangchun Sun1, Bin Li1, Lily Xu2 and Lingying Wu1

1 Department of Gynecologic Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

2 Chemistry Department, Wellesley College, Wellesley, MA, USA

Correspondence to:

Lingying Wu, email:

Keywords: ovarian cancer, early-stage, prognosis, survival, recurrence

Received: September 09, 2016 Accepted: October 14, 2016 Published: November 11, 2016


Some subsets of early stage ovarian cancer patients experience more recurrences than others. Studies on prognostics factors gave conflicting results. We investigated consecutive 221 patients with stage I/II ovarian cancer at our institution from 1999 to 2010. Univariate and multivariate analysis of progression free survival (PFS) and overall survival (OS) were performed. After a median follow-up of 79 months, the 5-year/10-year PFS and 5-year/10-year OS were 78% /76% and 90% /87% respectively. Multivariate analysis revealed that stage as the most prominent independent prognostic factor in terms of PFS (stage I vs stage IIA vs stage IIB, Hazard Ratio (HR): 1 vs 4 vs 6.1, P < 0.05) and OS (stage I vs stage II, HR: 1 vs 2.1, P < 0.05). Peritoneal biopsy reduced the risk of recurrence by 29% (95% CI: 0.15-0.58, P < 0.05). Ascites (HR = 2.8, 95% CI: 1.2-6.6, P < 0.05) and not the first-line chemotherapy (HR = 2.6, 95% CI: 1.1-6.5, P < 0.05) contributed to decreased OS. Overall, early-stage ovarian cancer had a favorable outcome, stage was the most powerful prognostic factor.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13317